Biomarin Pharmaceutical (BMRN) Share-based Compensation (2009 - 2026)

Biomarin Pharmaceutical's Share-based Compensation history runs 18 years deep, the most recent figure standing at $43.5 million for Q1 2026.

• Quarterly Share-based Compensation rose 12.07% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.1 million (up 220.34% YoY) and the FY2025 annual result came in at $181.4 million, up 133.9% from the prior year.
• Share-based Compensation was $43.5 million for Q1 2026 at Biomarin Pharmaceutical, down from $46.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $105.2 million in Q3 2022 and bottomed at -$95.3 million in Q4 2022.
• A 5-year average of $25.5 million and a median of $38.8 million in 2025 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 1746.53% in 2022, while the deepest fall reached 162.35% in 2022.
• Biomarin Pharmaceutical's Share-based Compensation stood at -$95.3 million in 2022, then soared by 104.11% to $3.9 million in 2023, then grew by 25.23% to $4.9 million in 2024, then surged by 855.65% to $46.9 million in 2025, then retreated by 7.36% to $43.5 million in 2026.
• Business Quant data shows BMRN's Share-based Compensation at $43.5 million in Q1 2026, $46.9 million in Q4 2025, and $49.3 million in Q3 2025.